Key points are not available for this paper at this time.
Real-world SGLT2 inhibitor use supports randomized trial data for the size effect of reduced hospitalization for heart failure in type 2 diabetes, although with a much lower ARR in people without CVD.
Hinton et al. (Fri,) studied this question.